Document Detail


Nonpharmacologic therapy for coronary artery atherosclerosis: results of primary and secondary prevention trials.
MedLine Citation:
PMID:  7977017     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The association between abnormal serum lipoprotein levels and coronary atherosclerosis has been established by extensive clinical, experimental, and epidemiologic evidence. Recent angiographic trials in patients with coronary artery disease have demonstrated that improvement in serum lipids and other risk factors has a favorable effect on coronary lesions and reduces coronary events and interventions. Most trials of coronary disease prevention have used intensive pharmacologic therapy, but several have involved only nonpharmacologic intervention. The latter investigations include both primary and secondary prevention studies. Three controlled, nonpharmacologic primary prevention trials with long-term follow-up used dietary management aimed at lowering serum cholesterol levels; one trial also included smoking cessation, and one used a comprehensive approach to risk-factor modification. Serum cholesterol levels and other risk factors were significantly decreased in the intervention groups but were unaltered in the control populations. After periods of 5 to 10 years, reductions of 20% to 45% in coronary events were observed in the intervention groups compared with controls. Four secondary intervention trials examined the effect of nonpharmacologic therapy alone on coronary artery disease regression; three of these trials included control groups. All of the trials focused on reduction of elevated serum cholesterol levels with a low-fat diet, and several included interventions for other risk factors. Serum cholesterol levels fell by 14% to 24% in treated patients compared with 4% to 9% in controls. Although these trials were of relatively short duration (1 to 3 years) and included small numbers of patients (36 to 90), each demonstrated favorable effects on coronary lesions and three revealed clinical benefits.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
E A Amsterdam; D Hyson; C T Kappagoda
Related Documents :
11303007 - An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased t...
9186277 - An index predicting coronary heart disease: ldl/hdl x 5.
15604317 - Statins for heart failure: at the crossroads between cholesterol reduction and pleiotro...
3059787 - Review of major intervention studies in hypertension and hyperlipidemia: focus on coron...
19950067 - Myocardial bridging and coronary artery anomalies detected by ecg-gated 64-row multidet...
16342217 - Aortic counterpulsation: a review of the hemodynamic effects and indications for use.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  American heart journal     Volume:  128     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  1994 Dec 
Date Detail:
Created Date:  1994-12-27     Completed Date:  1994-12-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1344-52     Citation Subset:  AIM; IM    
Affiliation:
Department of Internal Medicine, School of Medicine, University of California, Davis.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Coronary Artery Disease / epidemiology,  prevention & control*,  therapy*
Female
Humans
Male
Primary Prevention*
Risk Factors
Grant Support
ID/Acronym/Agency:
HL 01942-02/HL/NHLBI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Postmenopausal hormone therapy and atherosclerotic disease.
Next Document:  Oxygen free radicals and antioxidants: a review.